Supernus Pharmaceuticals, Inc.
(NASDAQ : SUPN)

( )
SUPN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corp. Plc
23.83%20.941.7%$162.94m
VRXValeant Pharmaceuticals International, Inc.
1.85%27.0114.1%$158.93m
BHCBausch Health Cos., Inc.
1.85%27.010.0%$119.66m
GWPHGW Pharmaceuticals Plc
-3.38%109.406.2%$81.05m
MDCOThe Medicines Co.
-3.58%53.3920.2%$78.63m
JAZZJazz Pharmaceuticals Plc
1.11%132.332.3%$69.12m
SAGESAGE Therapeutics, Inc.
-1.93%141.558.6%$52.41m
PRGOPerrigo Co. Plc
-1.67%48.286.8%$46.00m
ENDPEndo International Plc
0.61%4.148.8%$44.46m
HZNPHorizon Therapeutics Plc
0.73%30.236.6%$40.27m
UTHRUnited Therapeutics Corp.
-1.53%89.5714.3%$39.81m
ICPTIntercept Pharmaceuticals, Inc.
1.29%83.0216.9%$39.56m
ICLRICON plc
0.73%147.244.1%$37.50m
CTLTCatalent, Inc.
-0.74%49.482.4%$32.17m
AERIAerie Pharmaceuticals, Inc.
-0.89%18.886.8%$26.95m

Company Profile

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.